
    
      The study main inclusion criteria are:1.age≥18,KPS>70.2.anthracycline-pretreated patients
      with advanced breast cancer.3.at least 1 measurable lesion as defined by modified RECIST
      criteria.4.screening laboratory values within the following parameters:ANC
      ≥1.5×109/L,Hemoglobin≥10.0 g/dl，Platelet≥100×109/L. 5. signed ICF The patients will be
      randomised two group: docetaxol+capecitabine and docetaxol+cisplatin. According to AE, the
      dose will be adjusted.
    
  